Baricitinib plus Remdesivir shows promise for treating COVID-19
2 institutional releases
Published in New England Journal of Medicine · View the paper (DOI)
The combination of baricitinib and remdesivir reduced median time to recovery in hospitalized COVID-19 patients from eight days to seven days. Patients who required high-flow oxygen or non-invasive ventilation during their hospitalization showed the largest benefit, with a significant improvement in condition at day 15.
Coverage from 2 institutions
- Baricitinib plus Remdesivir shows promise for treating COVID-19 NIH/National Institute of Allergy and Infectious Diseases · Dec 11, 2020 · first to report
- New England Journal of Medicinepublishes COVID-19 treatment trial results University of Texas Health Science Center at San Antonio · Jan 14, 2021